I
Irras
Commercial-stage medical technology company
About Irras
IRRAS is a medical technology company specializing in advanced neuromonitoring and fluid management solutions for neurosurgical procedures. The company operates in the global healthcare market, primarily serving hospitals and medical institutions that require precise and reliable intracranial pressure (ICP) monitoring and drainage systems. IRRAS' core products include the Hummingbird ICP monitoring system and the IRRAflow intracranial drainage system. The Hummingbird ICP system offers the most accurate parenchymal ICP measurement with zero drift and multimodal monitoring through a single access point, making it a cost-efficient solution. The IRRAflow system is the first of its kind to combine automated irrigation and continuous ICP monitoring, providing a new standard of care for fluid management in neurosurgery. IRRAS generates revenue through the sale of these medical devices and related services, targeting a niche but critical segment of the healthcare industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2012
- Headquarters
- San Diego, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Ixora Ventures- VGVandel Group
European Investment Bank- BHBacara Holdings
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Irras on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Irras on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.